

1 **Effects of Hormone Therapy on survival, cancer, cardiovascular and dementia risks in 7 million**  
2 **menopausal women over age 65: a retrospective observational study**

3

4 Seo H. Baik<sup>1</sup>, Fitsum Baye,<sup>1</sup> Clement J. McDonald<sup>1</sup>

5

6 <sup>1</sup> Lister Hill National Center for Biomedical Communications, National Library of  
7 Medicine, National Institutes of Health, Bethesda, Maryland, U.S.A

8

9 **Abstract**

10 **Background**

11 The long-term influence of menopausal hormone therapy remains unanswered due to the  
12 termination of randomized clinical trials and discordant findings from observational studies.

13 **Methods**

14 From 2007-2019 enrollment records of 100% Medicare beneficiaries, we identified 7 million  
15 female enrollees aged 65 or more. We identified type, route and strength of estrogen based on  
16 their prescription drug utilization records. Using vital status record and encounter records, we  
17 defined the first onset of thirteen patient outcomes; all-cause mortality; 5 cancers (breast, lung,  
18 endometrial, colorectal, ovarian cancers); 6 CV conditions (ischemic heart diseases, heart failure,  
19 venous thromboembolism, stroke, atrial fibrillation, acute myocardial infarction); and dementia.  
20 Then, we implemented an extended Cox regression analysis to examine the effects of type, route,  
21 and strength of estrogens on each of 13 study outcomes.

22

23 **Findings**

## Effects of Hormone Therapy on survival, cancer, cardiovascular, and dementia risks

24 Estrogen monotherapy (ET) exhibited a significant, 20% (aHR=0.80; 95% CI 0.78-0.82), relative  
25 risk reduction of mortality. The reduction was greater with estradiol (aHR=0.78; 95% CI 0.75-  
26 0.80) than conjugated estrogen (aHR=0.86; 95% CI 0.85-0.88), and with vaginal (aHR=0.69;  
27 95% CI 0.65-0.74) than oral (aHR=0.89; 95% CI 0.87-0.90) and transdermal (aHR=0.78; 95% CI  
28 0.75-0.81) preparations. ET also exhibited significant risk *reductions* for all study cancers, breast  
29 (aHR=0.82; 95% CI 0.80-0.84), lung (aHR=0.87; 95% CI 0.84-0.90), endometrial (aHR=0.65;  
30 95% CI 0.62-0.69), colorectal (aHR=0.86; 95% CI 0.82-0.90) and ovarian (aHR=0.83; 95% CI  
31 0.79-0.88). ET slightly increased risks of ischemic heart diseases (aHR=1.03; 95% CI 1.01-1.04).  
32 However, such risk was not observed with low dose ET (aHR=0.98; 95% CI 0.97-0.99). Both  
33 combination therapy (aHR=1.11; 95% CI 1.08-1.14) and progestogen monotherapy (aHR=1.09;  
34 95% CI 1.05-1.13) exhibited a significantly increased risk of breast cancer. Oral HT exhibited a  
35 moderately increased risk of dementia.

## 36 **Conclusions**

37 Among female Medicare beneficiaries aged  $\geq 65$ , the effect of menopausal hormone therapy  
38 varies by type, route, and strength but overall estrogen seemed beneficial.

39

40

41

42

43

44

45

## Effects of Hormone Therapy on survival, cancer, cardiovascular, and dementia risks

### 46 **Introduction**

47 In 2002, the Women’s Health Initiatives (WHI) trial reported that menopausal  
48 estrogen+progestogen therapy (EPT) increased the occurrence of invasive breast cancer, stroke,  
49 and coronary heart disease in menopausal women (1) though it reduced fractures. The press  
50 dramatically presented the negative outcomes in a manner that some described as misleading  
51 (2,3). However, most of these results lost significance when corrected for multiple testing (1), and  
52 the second WHI study in 2004 examined the effect of estrogen monotherapy (ET) on these same  
53 outcomes and reported a near significant *reduction* in breast cancer (4), which became a  
54 significant 22% *reduction* in WHI’s long-term follow-up of that study (5). However, these  
55 positive results got little press attention and did little to reduce the fears about hormone therapy  
56 (HT) that had already implanted in the public’s mind. The WHI trials only studied one type  
57 (conjugated estrogen) and dosage (0.625 mg) and route (oral) of estrogen alone and in  
58 combination with a progestin. Many have wondered how different the results would have been  
59 with other types, routes, and dosage strengths of such medicines.

60  
61 The U.S. Centers for Medicare and Medicaid Services (CMS) Virtual Research Data Center  
62 (VRDC) (6) carries 13 years of prescription claims and 20 years of encounter claims (7,8) as well  
63 as vital status for most US women over 65, and thus menopausal. So, VRDC provides HT  
64 exposure data as well as outcomes data about death, dementia, cardiovascular (CV), and cancer  
65 conditions like those studied by the WHI trials. Furthermore, at least 2-7% of elderly women still  
66 use HT after age 65 (9), enough that VRDC data might shed light on the consequences of HT use  
67 in older women and is large enough to provide data about the effect of dose size, routes and types  
68 of estrogens that the WHI trials could not. We implemented an extended Cox regression analyses  
69 (10–12) to assess the association of these factors with death, dementia, CV and cancer outcomes.  
70 Here we report the results of these analyses.

## Effects of Hormone Therapy on survival, cancer, cardiovascular, and dementia risks

### 71 **Methods**

#### 72 Study population

73 The CMS provided us access to all records of Medicare Part A (hospital insurance), B (medical  
74 insurance), and D (prescription drug insurance), claims data for 100% Part D enrollees. We  
75 constrained our study sample to be women who were first entitled in Medicare near age 65 ( $\pm$  1  
76 month) and during the full years of Part D benefits (i.e., 2007–2019) —a total of 13 years. We  
77 only included enrollees with at least 6 months of data –to assure enough follow-up time.

78 We report usage trends broken down by year, HT type and route, using the number of Part D  
79 female enrollees in each year as the denominator. We report descriptive statistics of patients’  
80 demographics, socio-economic status, the prevalence of 49 chronic conditions, and the associated  
81 crude rates of outcomes.

82

#### 83 HT exposures

84 We classified HT into 6 related drug types, 4 routes and 3 dose strengths, as applicable. The drug  
85 types included estradiol (E2) alone, conjugated estrogen (CEE) alone, progestin (P) alone, E2+P  
86 combined, CEE+P combined and ethinyl estradiol (EE)+P combined. The routes include oral,  
87 transdermal, vaginal and injectable. We developed an average daily estrogen dose based on  
88 DailyMed (13) dosing instructions for each of 124 individual HT products (see full details in S1  
89 Table) which accommodated intermittent regimens (e.g., 21 days on and 7 days off). We defined  
90 a “standard” dose for estrogen type and route, based on the literature and the distribution of daily  
91 estrogen doses as 0.625 mg, 1 mg, and 5  $\mu$ g, for oral CEE, E2, and EE, respectively and 200  $\mu$ g  
92 and 50  $\mu$ g for non-oral, CEE and E2, respectively. For each drug type, we categorized this  
93 average daily estrogen doses into high, greater than 1.45 times the standard; low, less than 0.45

## Effects of Hormone Therapy on survival, cancer, cardiovascular, and dementia risks

94 times the standard; and medium, between the lower end of the high, and the upper end of the low,  
95 bounds. We considered each combination of estrogen type, dose strength, and route as separate  
96 covariates (22 of them). We considered subjects to be exposed to a study drug if they ever had a  
97 prescription for that drug prior to an outcome event.

98  
99 We only included HT medications with indications for menopausal symptoms and excluded the  
100 few indicated for birth control or for vaginal bleeding (injectable CEE). We did include injectable  
101 E2 which is indicated for menopausal symptoms (14,15). We did not include Megestrol in our  
102 study because of its special cancer uses.

103

### 104 Outcomes

105 Our goals were to describe the usage of HT in women age  $\geq 65$  and determine the influence of  
106 such usage on survival, and on the occurrence of WHI-like outcomes: 5 cancers, 6 cardiovascular  
107 (CV) conditions, and dementia (1,4). The cancer outcomes included breast, lung, endometrial,  
108 colorectal, and ovarian, cancers. The CV outcomes included: ischemic heart diseases (IHD), heart  
109 failure (HF), venous thromboembolism (VTE), stroke, atrial fibrillation (AFB), and acute  
110 myocardial infarction (AMI). The occurrence and onset date for all but ovarian cancer and VTE  
111 were predefined by algorithm in Medicare's Chronic Condition Data Warehouse (CCW) (16). We  
112 generated comparable occurrence data by examining ICD-9/10-CM codes for ovarian cancer  
113 (183.0 and C56) and VTE (415.1, 451, 453, I26, I80, I82), respectively.

114

### 115 Statistical analysis

## Effects of Hormone Therapy on survival, cancer, cardiovascular, and dementia risks

116 We explored the independent effect of each HT drug on the 13 outcomes listed above using  
117 separate extended Cox regression analyses. In each regression analysis, we included 22  
118 combinations of HT drug type, routes, and dose ranges as covariates. As adjustments for patients'  
119 characteristics, we also included race, degree of low-income-subsidy (LIS) (a surrogate for  
120 income (17)), rural residence indicator, calendar year of Medicare Part D enrollment (to adjust for  
121 secular trends), and the 47 CCW chronic conditions (16) with >1% prevalence, to adjust for  
122 overall medical burden. We treated all covariates except race as time-varying to avoid the risk of  
123 an immortal time bias and, protect against violations of proportional hazard assumption (10–12).  
124 When a cancer, or CV condition, or dementia was the outcome, we excluded all other cancer, CV  
125 conditions or dementia conditions, as covariates respectively.

126 Subjects became eligible for the study at the time of their Medicare entitlement, but prescription  
127 records were unavailable until their Part D enrollment. Many enrollees in our study also moved  
128 from Medicare Fee-For-Service (FFS) to a capitated plan (Medicare Advantage or MA) or  
129 disenrolled from Medicare. We had to censor them when that happened because we lost access to  
130 their encounter records and associated diagnose. We followed these subjects from their entry to  
131 Part D (while accounting for left truncation (18)) until they 1) experienced an outcome of interest,  
132 2) switched to a capitated plan, 3) disenrolled from Medicare or 4) reached 12/31/2019 (the end  
133 of our data availability), whichever came first. In order to 1) mitigate selection bias toward HT  
134 use and to 2) correct for potential bias from informative censoring, we developed 2 *time-varying*  
135 propensity scores (PSs) using logistic regressions (19–21). The first was for the likelihood of  
136 taking HT and the second for the likelihood of switching from Medicare FFS to a capitated plan  
137 or disenrolling from Medicare altogether and thus dropping out of the study. Both PSs were  
138 conditional probabilities based on patient's characteristics (demographics, socioeconomic, and  
139 presence of the 47 chronic conditions) and were iteratively estimated every 6 months among the  
140 patients who remained in follow-up considering all covariate values in a given 6-month cycle

## Effects of Hormone Therapy on survival, cancer, cardiovascular, and dementia risks

141 (21). We ran all Cox regression analyses with these time-varying PSs as additional adjustments  
142 (22,23).

143

### 144 Secondary analysis

145 In this study, enrollees who moved from Medicare FFS to a capitated plan or disenrolled from  
146 Medicare had to be censored. Because such censoring could be *informative* and result in  
147 censoring bias (24), we included a PS of such drop-outs as an extra covariate in our primary  
148 analysis. In addition to that, we performed an intention-to-treat (ITT) analysis (25) to assess the  
149 possibility that censoring bias accounted for the difference in mortality risk associated with HT  
150 use from our primary analysis. In this secondary analysis, we included all female beneficiaries  
151 who were still on FFS at one year post Part D enrollment and followed them until death or the  
152 end of the study (12/31/2019) while ignoring dropouts after one year. The covariates in this  
153 secondary analysis include our study drugs, and all of the other covariates used in our primary  
154 analysis but were time-fixed as of their values at or before the one-year cut-off. In addition, we  
155 also include the PS of taking any HT as of the one-year cut-off (i.e., time-fixed). This ITT  
156 analysis would result in more accurate estimates of drug efficacy than ones yielded from a per-  
157 protocol analysis (26). We report the relative risk for each study drug from this analysis.

158

## 159 **Results**

### 160 Study population and Secular trends

161 From 100% Part D senior female enrollees, more than 7 million satisfied our selection criteria.  
162 The death cohort, our largest, included 7,036,466 individuals, and a modest proportion, 15%, of

Effects of Hormone Therapy on survival, cancer, cardiovascular, and dementia risks

163 them used some type of HT at least once during our study period (Table 1). The disease-specific  
 164 cohorts were slightly smaller in number but had similar proportions of HT users.

165 **Table 1. Baseline Characteristics**

	<b>Any HT</b>	<b>Neither</b>
<b>N</b>	1,082,565	5,953,901
<b>Age at Part D Entry, Median (IQR)</b>	64.0(64.0-65.0)	64.0(64.0-65.0)
<b>Age at The End of Follow-Up, Median (IQR)</b>	71.0(68.0-74.0)	69.0(67.0-72.0)
<b>White</b>	965,436(89.2)	4,791,602(80.5)
<b>Black</b>	34,503(3.2)	465,960(7.8)
<b>Hispanic</b>	36,392(3.4)	350,606(5.9)
<b>Asian</b>	17,075(1.6)	177,022(3.0)
<b>Other</b>	29,159(2.7)	168,711(2.8)
<b>Ever Dual</b>	87,787(8.1)	1,004,457(16.9)
<b>Non-Dual LIS</b>	14,179(1.3)	156,754(2.6)
<b>Non-Dual No LIS</b>	980,599(90.6)	4,792,690(80.5)
<b>Living In Rural Area</b>	289,562(26.7)	1,605,895(27.0)
<b>Hysterectomy</b>	231,611(21.4)	639,809(10.7)
<b>Cataract</b>	718,924(66.4)	2,954,232(49.6)
<b>Chronic Kidney Disease</b>	221,782(20.5)	1,284,284(21.6)
<b>COPD</b>	174,424(16.1)	932,907(15.7)
<b>Diabetes</b>	240,201(22.2)	1,664,431(28.0)
<b>Glaucoma</b>	223,538(20.6)	952,997(16.0)
<b>Hip/Pelvic Fracture</b>	15,723(1.5)	82,706(1.4)
<b>Depression</b>	412,225(38.1)	1,727,657(29.0)
<b>Alzheimer's Disease or Senile Dementia</b>	63,605(5.9)	309,437(5.2)
<b>Osteoporosis</b>	268,653(24.8)	1,135,562(19.1)
<b>Rheumatoid Arthritis/Osteoarthritis</b>	657,040(60.7)	2,638,202(44.3)
<b>Anemia</b>	443,105(40.9)	2,035,431(34.2)
<b>Asthma</b>	167,973(15.5)	667,100(11.2)
<b>Hyperlipidemia</b>	811,559(75.0)	4,016,394(67.5)
<b>Hypertension</b>	721,052(66.6)	3,926,742(66.0)
<b>Hypothyroidism</b>	394,493(36.4)	1,576,154(26.5)
<b>Alcohol Use Disorders</b>	19,208(1.8)	115,692(1.9)
<b>Anxiety Disorders</b>	345,272(31.9)	1,363,862(22.9)
<b>Bipolar Disorder</b>	34,909(3.2)	143,139(2.4)
<b>Major Depressive Affective Disorder</b>	314,194(29.0)	1,290,630(21.7)
<b>Drug Use Disorder</b>	37,411(3.5)	157,354(2.6)
<b>Personality Disorders</b>	27,095(2.5)	93,976(1.6)
<b>Schizophrenia and other Psychotic Disorders</b>	18,016(1.7)	107,525(1.8)
<b>Epilepsy</b>	19,718(1.8)	110,771(1.9)



Effects of Hormone Therapy on survival, cancer, cardiovascular, and dementia risks

<b>Cystic Fibrosis and other Metabolic Developmental Disorders</b>	23,581(2.2)	83,419(1.4)
<b>Fibromyalgia, Chronic Pain and Fatigue</b>	439,070(40.6)	1,569,200(26.4)
<b>Viral Hepatitis (General)</b>	10,304(1.0)	62,552(1.1)
<b>Liver Disease Cirrhosis and other Liver Conditions (Excluding Hepatitis)</b>	105,312(9.7)	487,132(8.2)
<b>Leukemias and Lymphomas</b>	19,399(1.8)	92,685(1.6)
<b>Migraine and other Chronic Headache</b>	117,950(10.9)	327,037(5.5)
<b>Mobility Impairments</b>	20,922(1.9)	140,658(2.4)
<b>Obesity</b>	252,541(23.3)	1,634,171(27.4)
<b>Overarching OUD Disorder</b>	30,997(2.9)	105,841(1.8)
<b>Peripheral Vascular Disease</b>	112,913(10.4)	601,917(10.1)
<b>Tobacco Use Disorders</b>	78,084(7.2)	633,390(10.6)
<b>Pressure Ulcers and Chronic Ulcers</b>	35,812(3.3)	221,553(3.7)
<b>Sensory - Deafness and Hearing Impairment</b>	125,001(11.5)	399,956(6.7)

166

167 Note. Data are presented as No. (%) of patients unless otherwise noted.

168 Abbreviations: HT = Hormone Therapy; IQR = Interquartile Range; AMI = Acute Myocardial Infarction; COPD =

169 Chronic Obstructive Pulmonary Disease.

170

171 Over the 13 years of follow-up (2007-2019), the proportion of senior women taking any HT  
 172 containing estrogen dropped by half, from 11.4% to 5.8%. E2 tended to replace CEE; EPT  
 173 plummeted from 1.4% to a minuscule 0.2% (Figure 1a); and vaginal route tended to replace oral  
 174 route (Figure 1b). Overall, the number of ET users was 8 to 10 times greater than the number of  
 175 EPT or P alone users, respectively. Among ET users, the predominant route was vagina. Twice as  
 176 many women were on vaginal and 1/3<sup>rd</sup> as many on transdermal as on oral preparations. Among  
 177 EPT users, the most common type of EPT was E2+P, followed by CEE+P and then EE+P (Table  
 178 2). All prescriptions of EE+P were a combination of EE and norethindrone and we did not  
 179 include the 8% of the EE+P preparations indicated for birth control for consistency's sake though  
 180 that indication made no sense for our senior population.

181 **Figure 1. Trend in the use of Hormone Therapy (HT) by type and route**

182 (a) Secular Trend in HT use by type

183

184 (b) Secular Trend in HT use by route

Effects of Hormone Therapy on survival, cancer, cardiovascular, and dementia risks

185 **Table 2. Number (Percentage) of patients by Route, Type, and Strength in Death Cohort (N =**  
 186 **7,036,466)**

	N (%)
<b>Estrogen without Progestin</b>	990,315(14.1)
<b>By type</b>	
CEE	401,499(5.7)
E2	717,785(10.2)
<b>By route</b>	
Oral	314,514(4.5)
Transdermal	104,116(1.5)
Vaginal	668,052(9.5)
Injection	3,398(0.0)
<b>By dose</b>	
Low	334,299(4.8)
Medium	506,088(7.2)
High	390,817(5.6)
<b>Progestin without Estrogen</b>	100,712(1.4)
<b>Estrogen with Progestin</b>	127,174(1.8)
<b>By type</b>	
CEE	52,671(0.7)
E2	77,578(1.1)
EE	9,473(0.1)
<b>By route</b>	
Oral	109,739(1.6)
Transdermal	21,439(0.3)
<b>By dose</b>	
Low	60,804(0.9)
Medium	84,284(1.2)

187  
 188 Starting with Part D enrollment, the median follow-up in death cohort was 4.1 years (total of  
 189 33,171,664 person-years); it was longer among any HT users (5.8 years) than no HT users (3.9  
 190 years) (Table 3). Overall, 384,376 patients died (5.5% or 12 per 1000 person-years). The death  
 191 incidence was lower among HT users than no HT users (6 vs 13 per 1000 person-years). We  
 192 censored 1.5 out of 7 million subjects as they left FFS for MA plans (17.7%) or dis-enrolled from  
 193 Medicare (4.5%). The rate of censoring for this reason was higher among no HT users, indicating  
 194 potential bias from informative censoring. The number of subjects and follow-up duration varied

## Effects of Hormone Therapy on survival, cancer, cardiovascular, and dementia risks

195            somewhat across disease-specific cohorts because of different end points and censoring rates by

196            outcomes.

197

Table 3. Event/Censoring Points and Rates of Event/Death by Each Study Cohort

Outcome		N	End Points					Rate 1000 PPY	
			Event	Death	Censored at MA entry	Censored at Disenrollment	Censored at 12/31/2019	Event	Death
Death	any HT	1,082,565	N/A	39,577(3.7)	150,222(13.9)	35,504(3.3)	857,262(79.2)	N/A	6.08
	no HT	5,953,901	N/A	344,799(5.8)	1,092,537(18.3)	280,906(4.7)	4,235,659(71.1)	N/A	12.93
Breast cancer	any HT	1,052,546	40,022(3.8)	35,485(3.4)	144,121(13.7)	34,040(3.2)	798,878(75.9)	6.49	5.75
	no HT	5,680,297	272,143(4.8)	291,089(5.1)	1,023,231(18.0)	263,599(4.6)	3,830,235(67.4)	11.11	11.88
Lung cancer	any HT	1,078,052	11,288(1.0)	33,014(3.1)	149,387(13.9)	35,275(3.3)	849,088(78.8)	1.75	5.11
	no HT	5,922,463	81,085(1.4)	287,675(4.9)	1,085,123(18.3)	278,767(4.7)	4,189,813(70.7)	3.07	10.89
Endometrial cancer	any HT	1,077,618	8,994(0.8)	37,998(3.5)	148,967(13.8)	35,210(3.3)	846,449(78.5)	1.39	5.89
	no HT	5,923,782	61,594(1.0)	329,064(5.6)	1,082,244(18.3)	278,194(4.7)	4,172,686(70.4)	2.34	12.48
Colorectal cancer	any HT	1,075,782	8,403(0.8)	37,411(3.5)	148,792(13.8)	35,128(3.3)	846,048(78.6)	1.30	5.81
	no HT	5,917,758	59,779(1.0)	323,121(5.5)	1,080,922(18.3)	277,890(4.7)	4,176,046(70.6)	2.27	12.26
Ovarian cancer	any HT	1,078,089	6,780(0.6)	37,399(3.5)	149,311(13.8)	35,271(3.3)	849,328(78.8)	1.05	5.79
	no HT	5,929,939	37,104(0.6)	326,343(5.5)	1,086,482(18.3)	279,191(4.7)	4,200,819(70.8)	1.40	12.33
IHD	any HT	951,610	166,989(17.5)	18,049(1.9)	116,519(12.2)	28,180(3.0)	621,873(65.3)	33.00	3.57
	no HT	5,443,478	901,630(16.6)	163,325(3.0)	869,673(16.0)	230,529(4.2)	3,278,321(60.2)	41.67	7.55
CHF	any HT	1,044,298	77,330(7.4)	22,746(2.2)	138,138(13.2)	32,860(3.1)	773,224(74.0)	12.82	3.77
	no HT	5,766,670	498,335(8.6)	189,032(3.3)	994,579(17.2)	258,489(4.5)	3,826,235(66.4)	20.25	7.68
VTE	any HT	1,052,177	62,049(5.9)	27,509(2.6)	141,235(13.4)	33,494(3.2)	787,890(74.9)	10.17	4.51
	no HT	5,838,124	344,291(5.9)	243,558(4.2)	1,034,742(17.7)	267,052(4.6)	3,948,481(67.6)	13.64	9.65
Stroke	any HT	1,060,043	54,390(5.1)	30,427(2.9)	142,507(13.4)	33,623(3.2)	799,096(75.4)	8.79	4.92
	no HT	5,868,084	295,106(5.0)	270,101(4.6)	1,038,692(17.7)	267,162(4.6)	3,997,023(68.1)	11.56	10.58
AFB	any HT	1,053,942	49,421(4.7)	31,236(3.0)	143,595(13.6)	33,993(3.2)	795,697(75.5)	8.01	5.06
	no HT	5,836,153	283,134(4.9)	273,370(4.7)	1,046,200(17.9)	270,068(4.6)	3,963,381(67.9)	11.15	10.76
AMI	any HT	1,078,265	13,649(1.3)	36,361(3.4)	148,722(13.8)	35,178(3.3)	844,355(78.3)	2.12	5.64
	no HT	5,932,105	97,403(1.6)	312,394(5.3)	1,078,808(18.2)	277,336(4.7)	4,166,164(70.2)	3.70	11.85
Dementia	any HT	1,067,719	48,759(4.6)	29,032(2.7)	144,177(13.5)	33,804(3.2)	811,947(76.0)	7.75	4.61
	no HT	5,893,885	249,421(4.2)	263,399(4.5)	1,052,811(17.9)	269,694(4.6)	4,058,560(68.9)	9.63	10.17

199 **Notes:** Data are presented as No. (%) of patients unless otherwise noted.  
200 Abbreviations: HT = Hormone Therapy; PPY = Person-Per-Year; MA = Medicare Advantage; IHD = Ischemic  
201 Heart Disease; HF = Heart Failure; VTE = Venous thromboembolism; AFB = Atrial Fibrillation; AMI = Acute  
202 Myocardial Infarction.

203

204 Medicaid eligibility for special supplements was our proxy for income level. Accordingly, there  
205 were three income groups; dual (15%) with incomes below 135% of the Federal Poverty Line  
206 (FPL); non-dual LIS (2.4%) between 135% and 150% FPL; and non-dual no LIS (82.0%) above  
207 150% FLP (27). The proportions of non-Hispanic White and rural resident were 81.8% and  
208 26.9% respectively. Among the chronic conditions, hyperlipidemia (68.6%), hypertension  
209 (66.1%), and cataract (52.2%), were the most common (Table 1). Because we had no claims data  
210 about hysterectomies performed before age 65, hysterectomy data was only available for 12.4%  
211 of our cohort and most of it came from the ICD diagnosis codes for “acquired absence of  
212 uterus/cervix” (S2 Table).

### 213 Primary Analyses

214 In Tables 4 and 5, we present the marginal relative risk of 13 study outcomes associated with the  
215 use of each HT after controlling for all time-varying and time-fixed covariates including the use  
216 of any other HT beyond the index HT, namely adjusted hazard ratio (aHR). We report aHR as the  
217 percent of risk above (increased) or below (decreased) one by an amount of  $100 \times (aHR - 1)\%$ . We  
218 present marginal aHR by overall use of ET, EPT and Progestin to highlight average differences  
219 by type, route, and dose level. We also present aHR for each of 22 combinations of type, route,  
220 and dose level in Tables 6 and 7, where oral medium dose CEE and CEE+P indicate comparable  
221 drugs studied in the WHI trials.

222

223

224 **Table 4. Marginal effects of HT regimens on all-cause mortality and cancer outcomes.**

225

Marginal HT	(a) Death	(b) Death; ITT	(c) Breast	(d) Lung	(e) Endometrial	(f) Colorectal	(g) Ovarian
<b>Estrogen without Progestin</b>	0.80(0.78,0.82)‡	0.73(0.71,0.75)‡	0.82(0.80,0.84)‡	0.87(0.84,0.90)‡	0.65(0.62,0.69)‡	0.86(0.82,0.90)‡	0.83(0.79,0.88)‡
<b>By type</b>							
<b>CEE</b>	0.86(0.85,0.88)‡	0.85(0.84,0.87)‡	0.74(0.72,0.76)‡	0.91(0.88,0.94)‡	0.66(0.62,0.70)‡	0.89(0.85,0.93)‡	0.80(0.75,0.85)‡
<b>E2</b>	0.78(0.75,0.80)‡	0.68(0.66,0.71)‡	0.85(0.83,0.88)‡	0.86(0.81,0.90)‡	0.64(0.60,0.69)‡	0.84(0.79,0.90)‡	0.85(0.79,0.91)‡
<b>By route</b>							
<b>Oral</b>	0.89(0.87,0.90)‡	0.88(0.87,0.90)‡	0.75(0.73,0.76)‡	0.92(0.89,0.94)‡	0.59(0.56,0.62)‡	0.86(0.83,0.90)‡	0.79(0.75,0.83)‡
<b>Transdermal</b>	0.78(0.75,0.81)‡	0.66(0.63,0.69)‡	0.83(0.80,0.85)‡	0.84(0.79,0.89)‡	0.65(0.61,0.70)‡	0.83(0.77,0.89)‡	0.83(0.77,0.90)‡
<b>Vaginal</b>	0.69(0.65,0.74)‡	0.54(0.49,0.58)‡	0.94(0.90,0.98)‡	0.79(0.72,0.88)‡	0.82(0.74,0.91)‡	0.81(0.73,0.91)‡	0.97(0.87,1.08)
<b>Injection</b>	0.84(0.74,0.95)‡	1.08(0.94,1.24)	0.81(0.68,0.97)‡	1.01(0.80,1.26)	0.47(0.29,0.76)‡	1.11(0.82,1.52)	0.63(0.38,1.05)
<b>By dose</b>							
<b>Low</b>	0.79(0.77,0.81)‡	0.66(0.64,0.68)‡	0.86(0.85,0.88)‡	0.84(0.81,0.88)‡	0.72(0.68,0.75)‡	0.82(0.78,0.86)‡	0.86(0.81,0.90)‡
<b>Medium</b>	0.76(0.72,0.80)‡	0.65(0.60,0.69)‡	0.82(0.79,0.85)‡	0.84(0.77,0.91)‡	0.68(0.63,0.75)‡	0.83(0.76,0.92)‡	0.86(0.79,0.94)‡
<b>High</b>	0.84(0.82,0.87)‡	0.89(0.86,0.93)‡	0.78(0.75,0.82)‡	0.92(0.87,0.98)‡	0.57(0.51,0.64)‡	0.91(0.85,0.99)‡	0.78(0.70,0.88)‡
<b>Progestin without Estrogen</b>	0.98(0.94,1.01)	0.94(0.90,0.99)‡	1.09(1.05,1.13)†	0.91(0.84,0.98)‡	3.32(3.15,3.49)†	1.05(0.97,1.14)	1.67(1.55,1.81)†
<b>Estrogen with Progestin</b>	0.88(0.85,0.91)‡	0.78(0.75,0.81)‡	1.11(1.08,1.14)†	0.94(0.88,0.99)‡	0.65(0.59,0.71)‡	0.92(0.86,0.98)‡	1.01(0.94,1.09)
<b>By type</b>							
<b>CEE</b>	0.93(0.90,0.97)‡	0.83(0.80,0.87)‡	1.10(1.07,1.14)†	0.96(0.90,1.02)	0.72(0.66,0.78)‡	0.91(0.84,0.98)‡	1.09(1.01,1.19)†
<b>E2</b>	0.87(0.84,0.91)‡	0.78(0.74,0.82)‡	1.12(1.08,1.16)†	0.89(0.82,0.96)‡	0.72(0.67,0.78)‡	0.95(0.87,1.03)	0.99(0.91,1.08)
<b>EE</b>	0.83(0.76,0.92)‡	0.74(0.66,0.82)‡	1.11(1.03,1.19)†	0.99(0.84,1.16)	0.49(0.37,0.65)‡	0.88(0.72,1.08)	0.97(0.79,1.20)
<b>By route</b>							
<b>Oral</b>	0.89(0.86,0.92)‡	0.79(0.76,0.82)‡	1.11(1.08,1.14)†	0.96(0.90,1.02)	0.62(0.57,0.69)‡	0.90(0.83,0.97)‡	1.00(0.92,1.08)
<b>Transdermal</b>	0.83(0.75,0.91)‡	0.74(0.67,0.82)‡	1.10(1.03,1.18)†	0.82(0.70,0.97)‡	0.80(0.70,0.92)‡	1.04(0.89,1.23)	1.11(0.95,1.31)
<b>By dose</b>							
<b>Low</b>	0.88(0.82,0.94)‡	0.74(0.69,0.79)‡	1.06(1.01,1.11)†	0.96(0.86,1.07)	0.67(0.57,0.78)‡	0.85(0.74,0.97)‡	1.07(0.93,1.22)
<b>Standard</b>	0.88(0.84,0.92)‡	0.82(0.78,0.86)‡	1.15(1.11,1.19)†	0.92(0.85,0.99)‡	0.63(0.57,0.71)‡	0.97(0.89,1.06)	0.98(0.89,1.07)

226

227 **Notes:** Data are presented as adjusted Hazard Ratio (aHR) and its 95% Confidence Interval (CI).

228  $\uparrow$ = very significantly high with P-value < 0.001,  $\uparrow$ = significantly high with  $0.001 \leq$  P-value < 0.05

229  $\downarrow$ = very significantly low with P-value < 0.001,  $\downarrow$ = significantly low with  $0.001 \leq$  P-value < 0.05

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249 **Table 5. Marginal effects of HT regimens on CV outcomes and dementia**

250

Marginal HT	(a) IHD	(b) CHF	(c) VTE	(d) Stroke	(e) AFM	(f) AMI	(g) Dementia
<b>Estrogen without Progestin</b>	1.03(1.02,1.04)†	0.95(0.94,0.96)‡	0.96(0.95,0.98)‡	1.01(1.00,1.03)	0.95(0.93,0.97)‡	0.89(0.86,0.93)‡	0.98(0.96,0.99)‡
<b>By type</b>							
<b>CEE</b>	1.04(1.03,1.05)†	0.99(0.98,1.00)	0.97(0.96,0.99)‡	1.06(1.04,1.08)†	0.99(0.98,1.01)	0.93(0.90,0.96)‡	1.01(0.99,1.03)
<b>E2</b>	1.03(1.02,1.05)†	0.93(0.92,0.95)‡	0.96(0.94,0.98)‡	1.00(0.98,1.02)	0.93(0.91,0.95)‡	0.88(0.84,0.92)‡	0.96(0.94,0.99)‡
<b>By route</b>							
<b>Oral</b>	1.03(1.02,1.04)†	1.01(0.99,1.02)	0.97(0.96,0.99)‡	1.06(1.05,1.08)†	0.99(0.98,1.01)	0.93(0.91,0.96)‡	1.01(1.00,1.03)†
<b>Transdermal</b>	1.00(0.98,1.01)	0.89(0.87,0.91)‡	0.93(0.91,0.95)‡	0.94(0.92,0.97)‡	0.92(0.89,0.94)‡	0.87(0.82,0.92)‡	0.91(0.89,0.94)‡
<b>Vaginal</b>	1.03(1.00,1.05)†	0.87(0.84,0.90)‡	0.96(0.92,0.99)‡	0.98(0.94,1.02)	0.93(0.89,0.97)‡	0.83(0.75,0.91)‡	0.94(0.90,0.99)‡
<b>Injection</b>	1.19(1.10,1.28)†	1.17(1.06,1.29)†	1.02(0.91,1.15)	1.12(0.99,1.27)	0.86(0.74,0.99)‡	1.05(0.85,1.31)	1.08(0.95,1.22)
<b>By dose</b>							
<b>Low</b>	0.98(0.97,0.99)‡	0.86(0.85,0.88)‡	0.92(0.91,0.94)‡	0.94(0.92,0.95)‡	0.93(0.91,0.95)‡	0.83(0.80,0.86)‡	0.91(0.89,0.93)‡
<b>Medium</b>	1.02(1.00,1.04)†	0.93(0.90,0.96)‡	0.96(0.93,0.99)‡	1.00(0.97,1.04)	0.95(0.92,0.99)‡	0.88(0.82,0.95)‡	0.98(0.94,1.01)
<b>High</b>	1.09(1.07,1.11)†	1.05(1.03,1.08)†	1.00(0.97,1.03)	1.09(1.06,1.13)†	0.96(0.93,0.99)‡	0.96(0.91,1.01)	1.03(1.00,1.06)†
<b>Progestin without Estrogen</b>	1.03(1.01,1.05)†	1.04(1.01,1.07)†	1.03(1.00,1.06)	0.99(0.95,1.02)	1.04(1.01,1.08)†	0.86(0.81,0.93)‡	0.99(0.95,1.03)
<b>Estrogen with Progestin</b>	0.96(0.94,0.97)‡	0.89(0.87,0.91)‡	0.96(0.93,0.98)‡	0.93(0.90,0.95)‡	0.92(0.89,0.95)‡	0.93(0.87,0.98)‡	1.03(1.00,1.06)†
<b>By type</b>							
<b>CEE</b>	0.95(0.93,0.96)‡	0.91(0.89,0.94)‡	0.94(0.91,0.97)‡	0.93(0.90,0.96)‡	0.92(0.89,0.95)‡	0.95(0.90,1.01)	1.02(0.98,1.05)
<b>E2</b>	0.98(0.96,1.00)‡	0.89(0.86,0.92)‡	0.96(0.93,0.99)‡	0.93(0.90,0.96)‡	0.92(0.89,0.96)‡	0.95(0.88,1.02)	1.04(1.00,1.07)
<b>EE</b>	0.93(0.89,0.97)‡	0.87(0.81,0.94)‡	0.97(0.91,1.05)	0.92(0.85,1.00)	0.91(0.84,0.99)‡	0.87(0.73,1.03)	1.04(0.95,1.12)
<b>By route</b>							
<b>Oral</b>	0.94(0.93,0.96)‡	0.89(0.87,0.91)‡	0.96(0.93,0.98)‡	0.93(0.90,0.96)‡	0.91(0.88,0.94)‡	0.93(0.87,0.99)‡	1.03(1.00,1.07)†
<b>Transdermal</b>	1.03(1.00,1.07)	0.91(0.85,0.97)‡	0.96(0.90,1.02)	0.93(0.87,1.00)	0.98(0.91,1.05)	0.90(0.77,1.05)	1.01(0.94,1.09)
<b>By dose</b>							
<b>Low</b>	0.94(0.91,0.97)‡	0.87(0.83,0.92)‡	0.95(0.90,1.00)‡	0.90(0.85,0.96)‡	0.89(0.84,0.95)‡	0.88(0.78,0.98)‡	0.97(0.91,1.02)
<b>Standard</b>	0.97(0.95,0.99)‡	0.91(0.88,0.93)‡	0.96(0.93,0.99)‡	0.95(0.91,0.98)‡	0.94(0.90,0.97)‡	0.97(0.90,1.04)	1.08(1.04,1.12)†

251



252 **Notes:** Data are presented as adjusted Hazard Ratio (aHR) and its 95% Confidence Interval (CI).

253 Abbreviations: IHD = ischemic heart diseases; HF = heart failure; VTE = venous thromboembolism; AFB = atrial fibrillation; AMI = acute  
254 myocardial infarction.

255 †= very significantly high with P-value < 0.001, †= significantly high with  $0.001 \leq P\text{-value} < 0.05$

256 ‡= very significantly low with P-value < 0.001, ‡= significantly low with  $0.001 \leq P\text{-value} < 0.05$

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274 **Table 6. Hazard ratios of 22 HT regimens on all-cause mortality and cancer outcomes**

HT	(a) Death	(b) Death; ITT	(c) Breast	(d) Lung	(e) Endometrial	(f) Colorectal	(g) Ovarian
Oral CEE - Low Dose	0.84(0.81,0.87)↓	0.73(0.70,0.76)↓	0.77(0.74,0.80)↓	0.90(0.84,0.97)↓	0.62(0.56,0.69)↓	0.85(0.78,0.93)↓	0.78(0.70,0.87)↓
Oral CEE - Medium Dose	0.91(0.89,0.94)↓	0.91(0.89,0.94)↓	0.71(0.68,0.73)↓	0.90(0.86,0.95)↓	0.69(0.64,0.75)↓	0.86(0.80,0.92)↓	0.76(0.69,0.83)↓
Oral CEE - High Dose	0.95(0.90,1.00)↓	1.17(1.11,1.23)↑	0.66(0.60,0.72)↓	1.03(0.93,1.15)	0.48(0.39,0.60)↓	0.96(0.83,1.11)	0.73(0.60,0.91)↓
Oral E2 - Low Dose	0.85(0.82,0.88)↓	0.76(0.73,0.79)↓	0.78(0.75,0.81)↓	0.85(0.80,0.91)↓	0.62(0.56,0.68)↓	0.81(0.75,0.88)↓	0.82(0.75,0.90)↓
Oral E2 - Medium Dose	0.85(0.83,0.88)↓	0.81(0.78,0.84)↓	0.78(0.76,0.81)↓	0.88(0.83,0.93)↓	0.55(0.51,0.60)↓	0.87(0.81,0.93)↓	0.82(0.75,0.90)↓
Oral E2 - High Dose	0.92(0.87,0.98)↓	0.98(0.92,1.04)	0.79(0.74,0.84)↓	0.94(0.85,1.04)	0.58(0.49,0.68)↓	0.85(0.74,0.98)↓	0.81(0.69,0.96)↓
Transdermal E2 - Low Dose	0.78(0.72,0.85)↓	0.61(0.56,0.67)↓	0.90(0.85,0.96)↓	0.80(0.70,0.92)↓	0.75(0.65,0.85)↓	0.83(0.72,0.96)↓	0.78(0.67,0.91)↓
Transdermal E2 - Medium Dose	0.73(0.69,0.76)↓	0.63(0.60,0.66)↓	0.80(0.77,0.83)↓	0.85(0.78,0.92)↓	0.72(0.65,0.80)↓	0.84(0.76,0.92)↓	0.90(0.81,1.00)↓
Transdermal E2 - High Dose	0.83(0.77,0.88)↓	0.74(0.69,0.80)↓	0.78(0.73,0.83)↓	0.87(0.77,0.98)↓	0.51(0.44,0.60)↓	0.81(0.71,0.93)↓	0.82(0.71,0.96)↓
Vaginal CEE - Medium Dose	0.76(0.75,0.78)↓	0.67(0.66,0.69)↓	0.84(0.83,0.86)↓	0.79(0.77,0.83)↓	0.92(0.88,0.96)↓	0.90(0.86,0.94)↓	0.93(0.89,0.98)↓
Vaginal E2 - Low Dose	0.71(0.69,0.73)↓	0.54(0.52,0.56)↓	1.03(1.00,1.05)↑	0.81(0.77,0.85)↓	0.92(0.87,0.97)↓	0.78(0.73,0.83)↓	1.08(1.02,1.15)↑
Vaginal E2 - Medium Dose	0.60(0.46,0.77)↓	0.36(0.26,0.50)↓	1.00(0.85,1.17)	0.79(0.53,1.17)	0.59(0.39,0.90)↓	0.72(0.46,1.14)	0.92(0.60,1.40)
Vaginal E2 - High Dose	0.71(0.69,0.72)↓	0.63(0.61,0.65)↓	0.89(0.87,0.91)↓	0.79(0.76,0.82)↓	0.90(0.86,0.94)↓	0.87(0.83,0.91)↓	0.96(0.91,1.01)
Injection E2 - High Dose	0.84(0.74,0.95)↓	1.08(0.94,1.24)	0.81(0.68,0.97)↓	1.01(0.80,1.26)	0.47(0.29,0.76)↓	1.11(0.82,1.52)	0.63(0.38,1.05)
Oral CEE+P - Low Dose	0.90(0.85,0.95)↓	0.75(0.71,0.80)↓	1.03(0.98,1.08)	0.90(0.81,0.99)↓	0.72(0.64,0.82)↓	0.86(0.76,0.97)↓	1.13(1.00,1.28)
Oral CEE+P - Medium Dose	0.96(0.92,1.01)	0.93(0.88,0.97)↓	1.19(1.13,1.24)↑	1.02(0.93,1.12)	0.72(0.64,0.81)↓	0.95(0.85,1.07)	1.06(0.93,1.20)
Oral E2+P - Low Dose	0.87(0.80,0.94)↓	0.77(0.70,0.84)↓	1.07(1.01,1.13)↑	1.01(0.89,1.15)	0.64(0.56,0.74)↓	0.87(0.74,1.01)	0.97(0.83,1.13)
Oral E2+P - Medium Dose	0.93(0.87,0.99)↓	0.83(0.78,0.89)↓	1.19(1.13,1.25)↑	0.85(0.75,0.96)↓	0.73(0.64,0.83)↓	0.94(0.82,1.07)	0.91(0.79,1.05)
Oral EE+P - Low Dose	0.87(0.73,1.04)	0.69(0.57,0.84)↓	1.09(0.95,1.24)	0.98(0.73,1.31)	0.64(0.41,0.99)↓	0.82(0.57,1.18)	1.12(0.78,1.60)
Oral EE+P - Medium Dose	0.80(0.70,0.91)↓	0.78(0.69,0.89)↓	1.13(1.02,1.24)↑	1.00(0.81,1.24)	0.38(0.26,0.57)↓	0.95(0.74,1.23)	0.84(0.62,1.15)
Transdermal E2+P - Medium Dose	0.83(0.75,0.91)↓	0.74(0.67,0.82)↓	1.10(1.03,1.18)↑	0.82(0.70,0.97)↓	0.80(0.70,0.92)↓	1.04(0.89,1.23)	1.11(0.95,1.31)
Progestin monotherapy	0.98(0.94,1.01)	0.94(0.90,0.99)↓	1.09(1.05,1.13)↑	0.91(0.84,0.98)↓	3.32(3.15,3.49)↑	1.05(0.97,1.14)	1.67(1.55,1.81)↑

275

276 **Notes:** Data are presented as adjusted Hazard Ratio (aHR) and its 95% Confidence Interval (CI).

277 ↑= very significantly high with P-value &lt; 0.001, ↑= significantly high with 0.001 ≤ P-value &lt; 0.05

278 ↓= very significantly low with P-value &lt; 0.001, ↓= significantly low with 0.001 ≤ P-value &lt; 0.05

279

280 **Table 7. Hazard ratios of 22 HT regimens on CV outcomes and dementia**

HT	(a) IHD	(b) CHF	(c) VTE	(d) Stroke	(e) AFM	(f) AMI	(g) Dementia
Oral CEE - Low Dose	0.97(0.95,0.99)↓	0.89(0.87,0.92)↓	0.92(0.89,0.95)↓	0.97(0.94,1.00)	0.93(0.90,0.97)↓	0.90(0.84,0.96)↓	0.95(0.91,0.98)↓
Oral CEE - Medium Dose	1.04(1.02,1.05)↑	1.02(1.00,1.04)	0.98(0.95,1.00)	1.07(1.04,1.10)↑	1.01(0.98,1.03)	0.96(0.91,1.01)	1.00(0.97,1.02)
Oral CEE - High Dose	1.13(1.10,1.17)↑	1.19(1.14,1.24)↑	1.03(0.98,1.09)	1.25(1.19,1.32)↑	1.12(1.06,1.18)↑	1.00(0.91,1.11)	1.13(1.07,1.19)↑
Oral E2 - Low Dose	0.98(0.96,1.00)↓	0.91(0.89,0.93)↓	0.91(0.89,0.94)↓	0.95(0.92,0.98)↓	0.94(0.91,0.97)↓	0.88(0.83,0.93)↓	0.94(0.91,0.98)↓
Oral E2 - Medium Dose	1.01(1.00,1.03)	0.98(0.96,1.00)	0.98(0.95,1.00)	1.05(1.02,1.08)↑	0.96(0.93,0.98)↓	0.90(0.85,0.95)↓	1.02(0.99,1.05)
Oral E2 - High Dose	1.07(1.04,1.10)↑	1.08(1.03,1.12)↑	1.03(0.98,1.08)	1.11(1.06,1.17)↑	1.00(0.95,1.06)	0.95(0.86,1.05)	1.07(1.01,1.12)↑
Transdermal E2 - Low Dose	0.98(0.95,1.01)	0.84(0.79,0.88)↓	0.92(0.87,0.97)↓	0.90(0.85,0.95)↓	0.93(0.87,0.98)↓	0.82(0.72,0.93)↓	0.87(0.82,0.93)↓
Transdermal E2 - Medium Dose	1.00(0.98,1.02)	0.88(0.85,0.91)↓	0.94(0.90,0.97)↓	0.92(0.89,0.96)↓	0.93(0.90,0.97)↓	0.84(0.77,0.91)↓	0.94(0.90,0.98)↓
Transdermal E2 - High Dose	1.02(0.99,1.05)	0.96(0.91,1.00)	0.93(0.89,0.98)↓	1.01(0.96,1.07)	0.89(0.84,0.94)↓	0.95(0.85,1.06)	0.94(0.88,0.99)↓
Vaginal CEE - Medium Dose	1.02(1.01,1.03)↑	0.88(0.87,0.90)↓	0.97(0.95,0.98)↓	0.97(0.96,0.99)↓	0.93(0.91,0.94)↓	0.86(0.84,0.89)↓	0.98(0.96,0.99)↓
Vaginal E2 - Low Dose	0.99(0.98,1.00)	0.81(0.79,0.83)↓	0.94(0.92,0.96)↓	0.93(0.91,0.95)↓	0.91(0.89,0.94)↓	0.73(0.69,0.77)↓	0.88(0.86,0.90)↓
Vaginal E2 - Medium Dose	1.04(0.95,1.14)	0.88(0.76,1.03)	0.94(0.80,1.09)	1.01(0.86,1.20)	0.94(0.79,1.12)	0.86(0.60,1.25)	0.95(0.79,1.14)
Vaginal E2 - High Dose	1.06(1.05,1.08)↑	0.90(0.89,0.92)↓	0.98(0.96,1.00)↓	0.98(0.96,1.00)	0.95(0.93,0.96)↓	0.85(0.82,0.89)↓	0.97(0.95,0.98)↓
Injection E2 - High Dose	1.19(1.10,1.28)↑	1.17(1.06,1.29)↑	1.02(0.91,1.15)	1.12(0.99,1.27)	0.86(0.74,0.99)↓	1.05(0.85,1.31)	1.08(0.95,1.22)
Oral CEE+P - Low Dose	0.94(0.91,0.97)↓	0.87(0.84,0.91)↓	0.90(0.86,0.94)↓	0.89(0.84,0.93)↓	0.90(0.85,0.95)↓	0.91(0.82,1.00)	0.98(0.93,1.04)
Oral CEE+P - Medium Dose	0.95(0.93,0.98)↓	0.96(0.92,1.00)↓	0.98(0.93,1.02)	0.98(0.93,1.02)	0.94(0.90,0.99)↓	1.00(0.92,1.09)	1.05(1.00,1.10)↑
Oral E2+P - Low Dose	0.97(0.94,1.01)	0.89(0.84,0.94)↓	0.95(0.90,1.00)	0.93(0.87,0.99)↓	0.90(0.85,0.96)↓	1.02(0.90,1.15)	0.97(0.91,1.04)
Oral E2+P - Medium Dose	0.93(0.90,0.96)↓	0.87(0.83,0.92)↓	0.97(0.92,1.02)	0.93(0.88,0.98)↓	0.89(0.84,0.94)↓	0.94(0.84,1.05)	1.13(1.07,1.19)↑
Oral EE+P - Low Dose	0.91(0.84,0.99)↓	0.86(0.76,0.98)↓	1.00(0.88,1.14)	0.90(0.77,1.04)	0.88(0.75,1.03)	0.73(0.53,1.00)	0.95(0.81,1.10)
Oral EE+P - Medium Dose	0.95(0.89,1.01)	0.88(0.80,0.97)↓	0.95(0.86,1.05)	0.95(0.85,1.06)	0.94(0.84,1.06)	1.03(0.84,1.27)	1.13(1.02,1.26)↑
Transdermal E2+P - Medium Dose	1.03(1.00,1.07)	0.91(0.85,0.97)↓	0.96(0.90,1.02)	0.93(0.87,1.00)	0.98(0.91,1.05)	0.90(0.77,1.05)	1.01(0.94,1.09)
Progestin monotherapy	1.03(1.01,1.05)↑	1.04(1.01,1.07)↑	1.03(1.00,1.06)	0.99(0.95,1.02)	1.04(1.01,1.08)↑	0.86(0.81,0.93)↓	0.99(0.95,1.03)

281 **Notes:** Data are presented as adjusted Hazard Ratio (aHR) and its 95% Confidence Interval (CI).

282 Abbreviations: IHD = ischemic heart diseases; HF = heart failure; VTE = venous thromboembolism; AFB = atrial fibrillation; AMI = acute  
 283 myocardial infarction.

284 ↑= very significantly high with P-value < 0.001, ↑= significantly high with 0.001 ≤ P-value < 0.05

285 ↓= very significantly low with P-value < 0.001, ↓= significantly low with 0.001 ≤ P-value < 0.05

286 *The risk of all-cause mortality associated with HT use*

287 On average, ET use was associated with a significant, 20% reduction in mortality risk relative to  
288 no ET use (Table 4-a) which translated to 77,401 fewer expected deaths in our large population.  
289 All combinations of ET type, route, and dose were also associated with reduced mortality risk.  
290 The marginal risk of E2 on mortality was significantly less than that of CEE. Vaginal,  
291 transdermal, and oral preparation, in order by size of mortality risk, each had significantly less  
292 mortality risk than the one after. The mortality risk of low and medium doses were significantly  
293 less than high dose but were not different from each other. Overall, EPT was associated with  
294 significant 12% reduction in marginal risk of mortality. Progestin monotherapy had no significant  
295 association. Interestingly, oral CEE medium dose, comparable to the drug in the WHI trial of ET,  
296 exhibited less risk reduction in mortality (9%) than overall ET (Table 6-a).

297 The 6,405,685 patients (90% of those in the primary analysis) still in the study 12 months after  
298 Part D enrollment were the subjects for our ITT analysis. No censoring occurred after the 12-  
299 month cut-off in the ITT analysis; so, could not have shaped these results. Yet, marginal  
300 association between each type, route and dose level of HT and death from this analysis paralleled  
301 and exceeded the mortality reduction observed in the primary analysis (Table 3-b). So, the biases  
302 due to informative censoring are unlikely to account for the mortality reduction observed in the  
303 primary analysis.

304

305 *The risk of breast, lung, endometrial, colorectal, and ovarian, cancer associated with HT use*

306 During our study period, breast cancer incidence was four times that of any other study cancer  
307 (Table 3). ET use was associated with significant *reduction* in marginal risk of breast cancer, 18%  
308 overall, as well as within each combination of ET type, route, and dose size (Table 4-c). Oral ET

## Effects of Hormone Therapy on survival, cancer, cardiovascular, and dementia risks

309 exhibited significantly greater reductions than transdermal and transdermal ET significantly  
310 greater than vaginal. Furthermore, CEE was associated with significantly greater risk reduction  
311 for breast cancer than E2 – a pattern opposite to what we saw with mortality as the outcome. The  
312 intervention in WHI’s 13-year long-term follow-up postintervention study, oral CEE 0.625 mg,  
313 was associated with a 21% % risk reduction for breast cancer (5). Seventy percent of our oral  
314 CEE medium dose prescriptions were 0.625 mg, same strength as the WHI dose, 11% were  
315 greater (0.9 mg) and 19% less (0.45 mg) than 0.625 mg. In our study, oral CEE medium dose use  
316 was associated with a 29% risk reduction and was the second best among all oral ET (Table 6-c).  
317 To the negative, both EPT and progestin monotherapy significantly *increased* the risk of breast  
318 cancer (Table 3-c).

319 ET was associated with 13% and 14% decrease in the risks of lung and colorectal cancers,  
320 respectively. EPT also exhibited reductions in lung and colorectal cancer risks but by smaller  
321 amounts than ET. Progestin monotherapy was also associated with reduced lung cancer risk but  
322 had no association with colorectal cancer risk (Table 3-d & f).

323 With ET use, endometrial, and ovarian cancer risks declined moderately (Table 3-e & g) but this  
324 finding is likely an artifact of the selective use of ET in hysterectomized women who lack the  
325 organs where such cancers could arise. More than half of hysterectomized women also had  
326 bilateral oophorectomy (28). So, these two findings might not be meaningful. On the other hand,  
327 35% risk reduction of endometrial cancer associated with EPT use could be meaningful because it  
328 is usually prescribed for women with an intact uterus.

329

330 *The risk of IHD, CHF, VTE, Stroke, AFM, AMI, and Dementia, risk associated with HT*

## Effects of Hormone Therapy on survival, cancer, cardiovascular, and dementia risks

331 IHD occurred in more than a million subjects, twice the size of the next most frequent CV  
332 condition, CHF. So, ET's 3% increased risk of IHD is of overweight importance. Most types,  
333 routes and dose levels of ET were also associated with increased risk of IHD, up to 19% with the  
334 injectables, but less so (3-4%) in other types, route, and doses. Specifically, low dose oral CEE  
335 and E2 were associated with significant risk reduction for IHD by 3% and 2%, respectively  
336 (Table 7-a). Progestin monotherapy had the same 3% increased risk for IHD as ET. Interestingly,  
337 EPT formulations, overall, were associated with a significant 4% risk reduction of IHD (Table 4-  
338 a).

339 To the positive, ET use, overall, was associated with 5% decrease *in* the risk of CHF (Table 4-b).  
340 However, among the ET subgroups of high dose and injectable ET were associated with  
341 increased risk of CHF. As was true for IHD, all EPT formulations were associated with *reduced*  
342 CHF risk.

343 Overall ET use had small or no, associations with, stroke or dementia, risk (Table 4-d & g).  
344 However, high and medium doses of oral E2 and CEE had important increased risk of stroke,  
345 reaching 25% with high dose oral CEE (Table 7-d & g). Both estrogen types (CEE and E2) were  
346 also associated with increased dementia risk but only with high dose oral preparations.  
347 Transdermal and vaginal preparations of ET, that avoid first pass travel through the liver were  
348 associated with small *reduced* or null risk of both conditions, consistent with the results of other  
349 studies (29) and with the procoagulant and proinflammation effects of estrogen's liver passage  
350 (30,31). EPT use, on average, was also associated with small but significant, *increased* risk of  
351 dementia and, decreased risk of all 6 CV conditions.

352

353 **Discussion**

## Effects of Hormone Therapy on survival, cancer, cardiovascular, and dementia risks

354 This study is a population-based retrospective observational study that explored the associations  
355 between estrogen types, routes, and dose size and all-cause mortality, dementia, 5 common  
356 cancers, and 6 cardiovascular, conditions using an extended Cox regression analysis. Important  
357 limitations included that data availability only began at age 65; hysterectomy information was  
358 unavailable for most of our subjects.; we depended on claims for encounter diagnoses and could  
359 not validate them through chart review; and, as is true for all observational studies, differential  
360 influences of unmeasured confounders, such as adherence to healthy behavior among HT users,  
361 could have been present.

362 One strength was the use of filled prescription records, rather than patient recall, to ascertain HT  
363 use. Another strength was its size—a study population of more than 7 million menopausal  
364 women, nearly an order of magnitude larger than any previous HT study (32). Its large size let us  
365 estimate differences in associations between each of 22 HT drug type, route and dose  
366 combinations on the one hand and the many study outcomes on the other.

### 367 Association with all-cause mortality

368 ET use, overall, was associated with a 20% reduction in mortality risk considering all ET  
369 preparations together. The sole estrogen preparation studied in the WHI trials was 0.625 mg of  
370 oral CEE, and it exhibited a close to significant, 6% (HR=0.94; 95% CI 0.88-1.01) mortality  
371 reduction in the 18-year long-term follow-up of the WHI trails (33). This result gives some  
372 plausibility to the 9% mortality reduction we observed in association with the use of our medium  
373 dose, oral CEE which was almost identical to the drug randomized in WHI's estrogen only trial.  
374 In our study, vaginal E2 in low and medium doses were associated with greatest reduction of  
375 mortality risk (29-40%) (Table 6-a). Our overall mortality results are consistent with the mortality  
376 results from an meta-analysis of 31 observational and RCT studies that reported reduced  
377 mortality among HT users (34) and with the re-analyses of the Prostate, Lung, Colorectal, and

## Effects of Hormone Therapy on survival, cancer, cardiovascular, and dementia risks

378 Ovarian (PLCO) Cancer Screening RTC, which reported a 23% decrease in all-cause mortality  
379 among current users of any HT (35).

380

### 381 Associations with cancer

382 In our study, overall ET use and oral CEE medium dose use were associated with an 18% and  
383 29% reduction of breast cancer risk, respectively. The long-term follow-up of the WHI study  
384 reported a significant, and similarly sized, 21% reduction in breast cancer incidence (36) giving  
385 credence to this result.

386 In our study, ET use was also associated with significantly reduced colorectal (14%) and lung  
387 (13%) cancer risk as was EPT, but to a lesser degree. A few observational studies support our  
388 observations of reduced lung cancer rates in association with HT use (37,38), though there is  
389 controversy. Two observational studies (39,40) and a re-analysis of the PLCO trial data (35)  
390 support our protective associations between HT use and colorectal cancer. The greater incidence  
391 of colorectal (+79%) (41) and lung cancer (+26%) (42) among patients with lower level of  
392 estrogen due to oophorectomy as part of their hysterectomy compared to hysterectomized patients  
393 without ovary removal also support our results by implying that estrogen protects against these  
394 two cancers. On the downside, both EPT and progestin alone were associated with significant  
395 *increases* (11% and 9% respectively) in breast cancer risk.

396

### 397 Associations with CV disease and dementia

398 Our data revealed a 3% increase in risk for IHD with ET use compared to no use. However, this  
399 increased risk is concentrated in the use of high (9%) and medium (2%) dose levels. Low dose



## Effects of Hormone Therapy on survival, cancer, cardiovascular, and dementia risks

400 ET, used by one third of ET users, exhibited a salubrious, 2%, *decreased* risk for IHD. The  
401 associations between ET use and other CV conditions was also to the good—4-11% risk  
402 reductions. E2 and vaginal/transdermal compared to CEE and oral preparation exhibited  
403 numerically lower risks for all CV conditions. It further suggests that a similar decrease in  
404 dementia risk would accrue when low dose, topical (vaginal, transdermal) and E2, were  
405 prescribed and in stroke risk when low dose topicals and low dose oral E2 were prescribed.  
406 Topical ET preparations in our study, that would avoid the procoagulant and proinflammatory  
407 effects ascribed to liver passage (30,31), were associated with *reduced* risk of both conditions,  
408 consistent with the results of other studies (29).

409

### 410 Overall considerations

411 The risk reduction associated with various HT we saw generally favor less use of EPT, more use  
412 of the topical (vaginal or transdermal) rather than the oral route, use E2 rather than CEE, and low  
413 or medium dose rather than high dose for menopausal care. These advantages have been  
414 emphasized by others (43) and our trend data suggest prescribers have adopted them to some  
415 degree. However, our results on breast cancer are less consistent with patterns we saw with  
416 mortality as the outcome. ET use overall exhibited a decreased risk of breast cancer, but the  
417 reduction was significantly greater among CEE, oral route, and high dose, uses, than their counter  
418 parts. Further our EPT was used only by small subset of HT users (12%) and in that subset its use  
419 was associated with a reduction in the risk of endometrial cancer.

420 We did not include fractures as an outcome in our study. However, among the outcomes we  
421 included, we saw significant association with the use of specific HT medications that paralleled  
422 effects seen in each of the *significant* WHI end points including, the decreased incidence of  
423 colorectal cancer with both ET and EPT use (35), the decreased incidence of breast cancer with

## Effects of Hormone Therapy on survival, cancer, cardiovascular, and dementia risks

424 ET use, the increased incidence of breast cancer with EPT respectively and the decreased  
425 incidence of endometrial cancer with EPT use (36). These parallels give credence to our  
426 observational results.

427 Our follow-up began when women entered Medicare at about age 65, but it is likely that many of  
428 them started taking HT closer to the time of their menopausal symptoms and continued it into  
429 their Medicare years. If so, our positive results align with the timing hypotheses (44) that asserts  
430 HT use early in menopause is better than later, but extend it by reporting positive effects with  
431 usage continued into Medicare years. Such use is not a rarity per our data.

432 The FDA's black box warning about HT (45) extrapolates from the deleterious effect of EPT on  
433 breast cancer (1) and dementia (46) to all forms of ET, because no studies to the contrary existed  
434 then. Now, such studies do exist. The long-term WHI studies reported a significant decrease in  
435 breast cancer incidence (5) and death due to Alzheimer's disease (33), among patient in the ET  
436 study arm. Furthermore, many studies suggest that E2, topical routes, and low doses may produce  
437 better outcomes than CEE, oral and medium dose (0.625 mg) studied in the WHI's ET study  
438 (47,48).

439 Menopausal HT of all types has been maligned by the results of earliest WHI study (1), long  
440 public memory of the frightening media reports about it (2) and lack of attention to recent more  
441 positive studies. Our study though purely observational raises the *possibility* of important  
442 improvements in survival and reduction in the risk of three cancers. We hope our results  
443 stimulate, interest in hormone therapy and further observational studies using other large national  
444 database and biologic research, to support them.

445

446

## Effects of Hormone Therapy on survival, cancer, cardiovascular, and dementia risks

### 447 **Acknowledgement**

448 The authors thank Terry Therneau (PhD, Professor of Biostatistics, Mayo Clinic) for his guiding  
449 our use of time varying Cox regression to this data set and especially for the idea of using  
450 Intention to treat approach to identify biases due to censoring.

### 451 **Funding Statement**

452 This research was supported in part by the Intramural Research Program of the National Library  
453 of Medicine, National Institutes of Health. The authors received no specific funding for this work.

454

### 455 **Competing Interests Statement**

456 The authors do not have competing interests. The content is solely the responsibility of the  
457 authors and does not necessarily represent the official views of the National Library of Medicine,  
458 National Institutes of Health.

459

### 460 **Contributorship Statement**

461 SHB and CJM conceived and designed the study. SHB and FB performed the statistical analysis.  
462 SHB and CJM drafted the manuscript and all authors contributed substantially to the study.

463

### 464 **Data Availability Statement**

465 The Medicare claims data belong to CMS, and we do not have permission to publish the raw data.  
466 However, the data are available to researchers through the CMS Virtual Research Data Center.  
467 We have included almost all study results in our tables and supporting information.

## Effects of Hormone Therapy on survival, cancer, cardiovascular, and dementia risks

### 468           **References**

- 469    1.    The Women’s Health Initiative Steering Committee. Risks and Benefits of Estrogen Plus Progestin  
470           in Healthy Postmenopausal Women: Principal Results From the Women’s Health Initiative  
471           Randomized Controlled Trial. *JAMA J Am Med Assoc.* 2002 Jul 17;288(3):321–33.
- 472    2.    Brown S. Shock, terror and controversy: how the media reacted to the Women’s Health Initiative.  
473           <http://dx.doi.org/103109/136971372012660048> [Internet]. 2012 Jun [cited 2022 Mar  
474           21];15(3):275–80. Available from:  
475           <https://www.tandfonline.com/doi/abs/10.3109/13697137.2012.660048>
- 476    3.    Langer RD. The evidence base for HRT: what can we believe? *Climacteric* [Internet]. 2017 Mar 4  
477           [cited 2021 Apr 1];20(2):91–6. Available from:  
478           <https://www.tandfonline.com/action/journalInformation?journalCode=icmt20>
- 479    4.    The Women’s Health Initiative Steering Committee. Effects of Conjugated Equine Estrogen in  
480           Postmenopausal Women With Hysterectomy. *JAMA.* 2004 Apr 14;291(14):1701.
- 481    5.    Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, et al.  
482           Menopausal Hormone Therapy and Health Outcomes During the Intervention and Extended  
483           Poststopping Phases of the Women’s Health Initiative Randomized Trials. *JAMA* [Internet]. 2013  
484           Oct 2 [cited 2020 Apr 1];310(13):1353. Available from:  
485           <http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2013.278040>
- 486    6.    The Centers for Medicare & Medicaid Services. CMS Announces New Data Sharing Tool | CMS  
487           [Internet]. 2013 [cited 2019 Nov 1]. Available from: [https://www.cms.gov/newsroom/press-](https://www.cms.gov/newsroom/press-releases/cms-announces-new-data-sharing-tool)  
488           [releases/cms-announces-new-data-sharing-tool](https://www.cms.gov/newsroom/press-releases/cms-announces-new-data-sharing-tool)
- 489    7.    Administration for Community Living. *A Profile of Older Americans: 2018.* 2018.
- 490    8.    Cubanski J, Swoope C, Boccuti C, Jacobson G, Casillas G, Griffin S, et al. A Primer on Medicare  
491           [Internet]. 2015 [cited 2019 Feb 7]. Available from: [http://files.kff.org/attachment/report-a-primer-](http://files.kff.org/attachment/report-a-primer-on-medicare-key-facts-about-the-medicare-program-and-the-people-it-covers)  
492           [on-medicare-key-facts-about-the-medicare-program-and-the-people-it-covers](http://files.kff.org/attachment/report-a-primer-on-medicare-key-facts-about-the-medicare-program-and-the-people-it-covers)

Effects of Hormone Therapy on survival, cancer, cardiovascular, and dementia risks

- 493 9. Shreibati JB, Manson JAE, Margolis KL, Chlebowski RT, Stefanick ML, Hlatky MA. Impact of  
494 hormone therapy on Medicare spending in the Women’s Health Initiative randomized clinical  
495 trials. *Am Heart J* [Internet]. 2018 Apr 1 [cited 2020 Oct 28];198:108–14. Available from:  
496 /pmc/articles/PMC5901884/?report=abstract
- 497 10. Azzato EM, Greenberg D, Shah M, Blows F, Driver KE, Caporaso NE, et al. Prevalent cases in  
498 observational studies of cancer survival: do they bias hazard ratio estimates? *Br J Cancer*. 2009  
499 Jun 2;100(11):1806–11.
- 500 11. Shintani AK, Girard TD, Eden SK, Arbogast PG, Moons KGM, Ely EW. Immortal time bias in  
501 critical care research: application of time-varying Cox regression for observational cohort studies.  
502 *Crit Care Med*. 2009 Nov;37(11):2939–45.
- 503 12. Husain H, Thamrin SA, Tahir S, Mukhlisin A, Apriani M. The Application of Extended Cox  
504 Proportional Hazard Method for Estimating Survival Time of Breast Cancer. *IOP Conf Ser J Phys*  
505 *Conf Ser*. 2018;979:12087.
- 506 13. NATIONAL LIBRARY OF MEDICINE. DailyMed [Internet]. DailyMed. [cited 2020 Oct 29].  
507 Available from: <https://dailymed.nlm.nih.gov/dailymed/>
- 508 14. DailyMed - DEPO-ESTRADIOL- estradiol cypionate injection [Internet]. [cited 2021 Mar 24].  
509 Available from: <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9a4229fd-fecd-4ac1-9c4f-6d442533457f>
- 510
- 511 15. DailyMed - DELESTROGEN- estradiol valerate injection [Internet]. [cited 2021 Mar 24].  
512 Available from: <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e8f94df9-0692-4462-a7f0-fe019a0a3f07>
- 513
- 514 16. The Chronic Condition Warehouse. Chronic Conditions Data Warehouse: CCW Chronic  
515 Condition Algorithms [Internet]. [cited 2017 Jan 23]. Available from:  
516 <https://www.ccwdata.org/web/guest/condition-categories>
- 517 17. Baik SH, Fung K-W, McDonald CJ. The mortality risk of Proton Pump Inhibitors in 1.9 Million  
518 US Seniors: an extended Cox survival analysis. *Clin Gastroenterol Hepatol*. 2021 Jan 13;

Effects of Hormone Therapy on survival, cancer, cardiovascular, and dementia risks

- 519 18. Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models.  
520 Stat Med. 2007 May 20;26(11):2389–430.
- 521 19. Rosenbaum PR, Rubin DB. The Central Role of the Propensity Score in Observational Studies for  
522 Causal Effects. *Biometrika*. 1983;70(1):41–55.
- 523 20. Willems SJW, Schat A, van Noorden MS, Fiocco M. Correcting for dependent censoring in  
524 routine outcome monitoring data by applying the inverse probability censoring weighted  
525 estimator. *Stat Methods Med Res* [Internet]. 2018 Feb 1 [cited 2022 Jan 25];27(2):323–35.  
526 Available from: <https://pubmed.ncbi.nlm.nih.gov/26988930/>
- 527 21. Wyss R, Gagne JJ, Zhao Y, Zhou EH, Major JM, Wang S V., et al. Use of Time-Dependent  
528 Propensity Scores to Adjust Hazard Ratio Estimates in Cohort Studies with Differential Depletion  
529 of Susceptibles. *Epidemiology* [Internet]. 2020 Jan 1 [cited 2022 Jan 27];31(1):82–9. Available  
530 from:  
531 [https://journals.lww.com/epidem/Fulltext/2020/01000/Use\\_of\\_Time\\_Dependent\\_Propensity\\_Scor](https://journals.lww.com/epidem/Fulltext/2020/01000/Use_of_Time_Dependent_Propensity_Scores_to_Adjust.9.aspx)  
532 [es\\_to\\_Adjust.9.aspx](https://journals.lww.com/epidem/Fulltext/2020/01000/Use_of_Time_Dependent_Propensity_Scores_to_Adjust.9.aspx)
- 533 22. Spreeuwenberg MD, Bartak A, Croon MA, Hagenaaars JA, Busschbach JJV, Andrea H, et al. The  
534 multiple propensity score as control for bias in the comparison of more than two treatment arms:  
535 An introduction from a case study in mental health. *Med Care* [Internet]. 2010 Feb [cited 2022 Feb  
536 7];48(2):166–74. Available from: [https://journals.lww.com/lww-](https://journals.lww.com/lww-medicalcare/Fulltext/2010/02000/The_Multiple_Propensity_Score_as_Control_for_Bias.12.aspx)  
537 [medicalcare/Fulltext/2010/02000/The\\_Multiple\\_Propensity\\_Score\\_as\\_Control\\_for\\_Bias.12.aspx](https://journals.lww.com/lww-medicalcare/Fulltext/2010/02000/The_Multiple_Propensity_Score_as_Control_for_Bias.12.aspx)
- 538 23. Adams H, Adams HHH, Jackson C, Rincon-Torroella J, Jallo GI, Quiñones-Hinojosa A.  
539 Evaluating extent of resection in pediatric glioblastoma: a multiple propensity score-adjusted  
540 population-based analysis. *Child’s Nerv Syst* [Internet]. 2016 Mar 1 [cited 2022 Feb 7];32(3):493–  
541 503. Available from: <https://link.springer.com/article/10.1007/s00381-015-3006-x>
- 542 24. Ranganathan P, Pramesh CS. Censoring in survival analysis: Potential for bias. *Perspect Clin Res*  
543 [Internet]. 2012 [cited 2022 Mar 8];3(1):40. Available from: [/pmc/articles/PMC3275994/](https://pubmed.ncbi.nlm.nih.gov/2375994/)
- 544 25. Olijnyk L, Darsaut TE, Öhman J, Raymond J. Understanding intent to treat analyses: An important

Effects of Hormone Therapy on survival, cancer, cardiovascular, and dementia risks

- 545 lesson from the international cooperative study on the timing of aneurysm surgery. *Neurochirurgie*  
546 [Internet]. 2022 Feb [cited 2022 Mar 23]; Available from:  
547 <https://pubmed.ncbi.nlm.nih.gov/35143810/>
- 548 26. McCoy CE. Understanding the Intention-to-treat Principle in Randomized Controlled Trials. *West*  
549 *J Emerg Med* [Internet]. 2017 Oct 1 [cited 2022 Mar 7];18(6):1075. Available from:  
550 </pmc/articles/PMC5654877/>
- 551 27. Samson LW, Finegold K, Ahmed A, Jensen M, Filice CE, Joynt KE. Examining Measures of  
552 Income and Poverty in Medicare Administrative Data. *Med Care* [Internet]. 2017 Dec [cited 2021  
553 Mar 23];55(12):e158–63. Available from: <https://journals.lww.com/00005650-201712000-00024>
- 554 28. Parker WH. Bilateral Oophorectomy versus Ovarian Conservation: Effects on Long-term  
555 Women’s Health. *J Minim Invasive Gynecol*. 2010 Mar 1;17(2):161–6.
- 556 29. Mohammed K, Dabrh AMA, Benkhadra K, Al Nofal A, Carranza Leon BG, Prokop LJ, et al. Oral  
557 vs transdermal estrogen therapy and vascular events: A systematic review and meta-analysis. *J*  
558 *Clin Endocrinol Metab* [Internet]. 2015 Nov 1 [cited 2022 Mar 29];100(11):4012–20. Available  
559 from: <https://academic.oup.com/jcem/article/100/11/4012/2836071>
- 560 30. Vehkavaara S, Silveira A, Hakala-Ala-Pietilä T, Virkamäki A, Hovatta O, Hamsten A, et al.  
561 Effects of oral and transdermal estrogen replacement therapy on markers of coagulation,  
562 fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. *Thromb*  
563 *Haemost* [Internet]. 2001 Dec 8 [cited 2022 Mar 28];85(4):619–25. Available from:  
564 <http://www.thieme-connect.com/products/ejournals/html/10.1055/s-0037-1615643>
- 565 31. Luyer MDP, Khosla S, Owen WG, Miller VM. Prospective Randomized Study of Effects of  
566 Unopposed Estrogen Replacement Therapy on Markers of Coagulation and Inflammation in  
567 Postmenopausal Women. *J Clin Endocrinol Metab* [Internet]. 2001 Aug 1 [cited 2022 Mar  
568 28];86(8):3629–34. Available from: <https://academic.oup.com/jcem/article/86/8/3629/2848792>
- 569 32. Banks E, Beral V, Bull D, Reeves G, Austoker J, English R, et al. Breast cancer and hormone-  
570 replacement therapy in the Million Women Study. *Lancet* (London, England) [Internet]. 2003 Aug

Effects of Hormone Therapy on survival, cancer, cardiovascular, and dementia risks

- 571 9 [cited 2022 Mar 10];362(9382):419–27. Available from:  
572 <https://pubmed.ncbi.nlm.nih.gov/12927427/>
- 573 33. Manson JAE, Aragaki AK, Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, et al.  
574 Menopausal hormone therapy and long-term all-cause and cause-specific mortality: The Women’s  
575 Health Initiative randomized trials. *JAMA - J Am Med Assoc*. 2017 Sep 12;318(10):927–38.
- 576 34. Stute P, Stadler A, Heufelder A. The impact of menopausal hormone therapy on overall mortality  
577 – a comprehensive review. <https://doi.org/10.1080/1369713720201767568> [Internet]. 2020 Sep 2  
578 [cited 2022 Apr 11];23(5):447–59. Available from:  
579 <https://www.tandfonline.com/doi/abs/10.1080/13697137.2020.1767568>
- 580 35. Symer MM, Wong NZ, Abelson JS, Milsom JW, Yeo HL. Hormone Replacement Therapy and  
581 Colorectal Cancer Incidence and Mortality in the Prostate, Lung, Colorectal, and Ovarian Cancer  
582 Screening Trial. *Clin Colorectal Cancer*. 2018 Jun 1;17(2):e281–8.
- 583 36. Espeland MA, Shumaker SA, Leng I, Manson JE, Brown CM, LeBlanc ES, et al. Long-Term  
584 Effects on Cognitive Function of Postmenopausal Hormone Therapy Prescribed to Women Aged  
585 50 to 55 Years. *JAMA Intern Med* [Internet]. 2013 Aug 12 [cited 2022 Apr 6];173(15):1429–36.  
586 Available from: <https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/1726979>
- 587 37. Schwartz AG, Wenzlaff AS, Prysak GM, Murphy V, Cote ML, Brooks SC, et al. Reproductive  
588 factors, hormone use, estrogen receptor expression and risk of non-small-cell lung cancer in  
589 women. *J Clin Oncol*. 2007 Dec 20;25(36):5785–92.
- 590 38. Pesatori AC, Carugno M, Consonni D, Hung RJ, Papadopoulos A, Landi MT, et al. Hormone use  
591 and risk for lung cancer: a pooled analysis from the International Lung Cancer Consortium  
592 (ILCCO). *Br J Cancer* 2013 1097 [Internet]. 2013 Sep 3 [cited 2022 Mar 11];109(7):1954–64.  
593 Available from: <https://www.nature.com/articles/bjc2013506>
- 594 39. Newcomb PA, Zheng Y, Chia VM, Morimoto LM, Doria-Rose VP, Templeton A, et al. Estrogen  
595 Plus Progestin Use, Microsatellite Instability, and the Risk of Colorectal Cancer in Women.  
596 *Cancer Res* [Internet]. 2007 Aug 1 [cited 2022 Mar 29];67(15):7534–9. Available from:



Effects of Hormone Therapy on survival, cancer, cardiovascular, and dementia risks

- 597 [https://aacrjournals.org/cancerres/article/67/15/7534/533438/Estrogen-Plus-Progestin-Use-](https://aacrjournals.org/cancerres/article/67/15/7534/533438/Estrogen-Plus-Progestin-Use-Microsatellite)  
598 [Microsatellite](https://aacrjournals.org/cancerres/article/67/15/7534/533438/Estrogen-Plus-Progestin-Use-Microsatellite)
- 599 40. Delellis Henderson K, Duan L, Sullivan-Halley J, Ma H, Clarke CA, Neuhausen SL, et al.  
600 Menopausal hormone therapy use and risk of invasive colon cancer: the California Teachers  
601 Study. *Am J Epidemiol* [Internet]. 2010 Feb [cited 2022 Mar 9];171(4):415–25. Available from:  
602 <https://pubmed.ncbi.nlm.nih.gov/20067917/>
- 603 41. Koch T, Therning Jørgensen J, Christensen J, Duun-Henriksen AK, Priskorn L, Kildevæld  
604 Simonsen M, et al. Bilateral oophorectomy and rate of colorectal cancer: A prospective cohort  
605 study. *Int J Cancer* [Internet]. 2022 Jan 1 [cited 2022 Mar 11];150(1):38–46. Available from:  
606 <https://onlinelibrary.wiley.com/doi/full/10.1002/ijc.33776>
- 607 42. Parker WH. Ovarian conservation versus bilateral oophorectomy at the time of hysterectomy for  
608 benign disease. *Menopause* [Internet]. 2014 Feb [cited 2022 Mar 11];21(2):192–4. Available from:  
609 [https://journals.lww.com/menopausejournal/Fulltext/2014/02000/Ovarian\\_conservation\\_versus\\_bi-](https://journals.lww.com/menopausejournal/Fulltext/2014/02000/Ovarian_conservation_versus_bilateral_oophorectomy.16.aspx)  
610 [lateral\\_oophorectomy.16.aspx](https://journals.lww.com/menopausejournal/Fulltext/2014/02000/Ovarian_conservation_versus_bilateral_oophorectomy.16.aspx)
- 611 43. Speth RC, D’ambra M, Ji H, Sandberg K. A heartfelt message, estrogen replacement therapy: use  
612 it or lose it. *Am J Physiol Heart Circ Physiol* [Internet]. 2018 Dec 1 [cited 2022 Apr  
613 6];315(6):H1765–78. Available from: <https://pubmed.ncbi.nlm.nih.gov/30216118/>
- 614 44. Hodis HN, Collins P, Mack WJ, Schierbeck LL. The timing hypothesis for coronary heart disease  
615 prevention with hormone therapy: past, present and future in perspective. *Climacteric* [Internet].  
616 2012 Jun 22 [cited 2021 Apr 9];15(3):217–28. Available from:  
617 <http://www.tandfonline.com/doi/full/10.3109/13697137.2012.656401>
- 618 45. U.S. Food and Drug Administration. Estrace Tablets.
- 619 46. Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, et al. Estrogen Plus  
620 Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal  
621 Women - The Women’s Health Initiative Memory Study: A Randomized Controlled Trial. *J Am*  
622 *Med Assoc* [Internet]. 2003 May 28 [cited 2021 Mar 24];289(20):2651–62. Available from:

Effects of Hormone Therapy on survival, cancer, cardiovascular, and dementia risks

623 [www.jama.com](http://www.jama.com)

624 47. Yaffe K, Vittinghoff E, Ensrud KE, Johnson KC, Diem S, Hanes V, et al. Effects of Ultra-Low-  
625 Dose Transdermal Estradiol on Cognition and Health-Related Quality of Life. *Arch Neurol*  
626 [Internet]. 2006 Jul 1 [cited 2022 Apr 11];63(7):945–50. Available from:  
627 <https://jamanetwork.com/journals/jamaneurology/fullarticle/791814>

628 48. Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. Estrogen therapy and risk  
629 of cognitive decline: Results from the Women’s Estrogen for Stroke Trial (WEST). *Am J Obstet*  
630 *Gynecol*. 2005 Feb 1;192(2):387–93.

631

632

633

634

635

636

637

638

639

640

641

642

643

644

645

646

647

648

649

650

Effects of Hormone Therapy on survival, cancer, cardiovascular, and dementia risks

651 **Supporting information**

652 **Description of S1 Table**


653 **S1 Table. All menopausal hormone therapy estrogen and progestin drugs available in Medicare**  
654 **prescription drug claims data during our 13-year study.**

655 **S2 Table. List of CPT AND ICD Diagnosis and Procedure codes used to define the absence of a**  
656 **uterus or hysterectomy surgery.**

657

**Figure 1. Trend in the use of Hormone Therapy (HT) by type and route**

**(a) Secular Trend in HT use by type**



**(b) Secular Trend in HT use by route**

